<DOC>
	<DOC>NCT00798148</DOC>
	<brief_summary>This trial is studying how well iodine I 131 metaiodobenzylguanidine together with combination chemotherapy works in treating patients who are undergoing an autologous peripheral stem cell for high risk or relapsed neuroblastoma.</brief_summary>
	<brief_title>131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Histologically confirmed Neuroblastoma and/or demonstration of tumor cells in bone marrow with elevated urinary catecholamine metabolites High risk according COG (Children Oncology Group)OR Relapse OR Refractory As at least one I131MIBG avid target lesion determined by diagnostic MIBG scan Glomerular filtration rate or creatinine clearance &gt; 60 ml/min No tumor cell in Bone Marrow by routine morphology aspiration and biopsy before peripheral stem cell collection No active infection Impaired renal function No avid I131MIBG lesion Active infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>MIBG</keyword>
	<keyword>Autologous Peripheral Stem Cell Transplantation</keyword>
</DOC>